WuXi Vaccines

Viral Vaccines Process Development

Leveraging WuXi Biologics’ HEK 293 Cells for Optimal Performance

Commercial media and chemically defined media preferred Viral Vaccine Cell Culture Process Development

- Adherent cell culture (Cell Factory / cell STAK, iCellis fixed-bed bioreactor) and microcarrier-based adherent cell culture
- Suspension cell culture (Bioreactor)

Virus Purification Process Development

Innovations To Increase Virus Titer

Suspension Cell Culture	Intensified cell culture process using perfusion (ATF-based), to increase cell density 2–5 fold N-1 perfusion in wave system to reduce total cell expansion and overall production timelines Cell culture scaling-up from bench scale to 200 L, and up to 2,000 L
Adherent Cell Culture	Perfusion-based microcarrier cell culture in single-use bioreactors increase titers efficiently than a typical cell factory Fixed-bed bioreactor, (e.g., iCellis), to greatly increase volumetric titer